Christopher Yea
Corporate Officer/Principal bij KALVISTA PHARMACEUTICALS, INC.
Vermogen: 839 976 $ op 30-04-2024
Actieve functies van Christopher Yea
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
KALVISTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-11-2016 | - |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Corporate Officer/Principal | 01-11-2015 | - |
Loopbaan van Christopher Yea
Eerdere bekende functies van Christopher Yea
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Vantia Ltd.
Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Operationeel Directeur | 01-01-2008 | 01-11-2015 |
Oprichter | 01-01-2008 | 01-11-2015 |
Opleiding van Christopher Yea
University of Bristol | Doctorate Degree |
Statistieken
Internationaal
Verenigd Koninkrijk | 4 |
Verenigde Staten | 2 |
Operationeel
Corporate Officer/Principal | 2 |
Chief Operating Officer | 1 |
Founder | 1 |
Sectoraal
Health Technology | 3 |
Commercial Services | 2 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
KALVISTA PHARMACEUTICALS, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Vantia Ltd.
Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Commercial Services |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Health Technology |
- Beurs
- Insiders
- Christopher Yea
- Ervaring